Lanadelumab: meta-analysis of COVID-19 studies

0 0.5 1 1.5+ All studies -7% 1 55 Improvement, Studies, Patients Relative Risk Mortality -7% 1 55 RCTs -7% 1 55 Late -7% 1 55 Lanadelumab for COVID-19 c19early.org December 2025 Favorslanadelumab Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ COMMUNITY Amgen (DB RCT) -7% 1.07 [0.48-2.35] death 8/25 9/30 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.88 Late treatment -7% 1.07 [0.48-2.35] 8/25 9/30 7% higher risk All studies -7% 1.07 [0.48-2.35] 8/25 9/30 7% higher risk 1 lanadelumab COVID-19 study c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.88 Effect extraction pre-specified(most serious outcome) Favors lanadelumab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ COMMUNITY Amgen (DB RCT) -7% 1.07 [0.48-2.35] 8/25 9/30 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.88 Late treatment -7% 1.07 [0.48-2.35] 8/25 9/30 7% higher risk All studies -7% 1.07 [0.48-2.35] 8/25 9/30 7% higher risk 1 lanadelumab COVID-19 mortality result c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.88 Favors lanadelumab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ COMMUNITY Amgen (DB RCT) -7% 1.07 [0.48-2.35] death 8/25 9/30 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.88 Late treatment -7% 1.07 [0.48-2.35] 8/25 9/30 7% higher risk All studies -7% 1.07 [0.48-2.35] 8/25 9/30 7% higher risk 1 lanadelumab COVID-19 serious outcome c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.88 Effect extraction pre-specified(most serious outcome) Favors lanadelumab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ COMMUNITY Amgen (DB RCT) 24% 0.76 [0.35-1.67] no disch. 7/25 11/30 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.51 Late treatment 24% 0.76 [0.35-1.67] 7/25 11/30 24% lower risk All studies 24% 0.76 [0.35-1.67] 7/25 11/30 24% lower risk 1 lanadelumab COVID-19 recovery result c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.51 Favors lanadelumab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ COMMUNITY Amgen (DB RCT) -7% 1.07 [0.48-2.35] death 8/25 9/30 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.88 Late treatment -7% 1.07 [0.48-2.35] 8/25 9/30 7% higher risk All studies -7% 1.07 [0.48-2.35] 8/25 9/30 7% higher risk 1 lanadelumab COVID-19 Randomized Controlled Trial c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.88 Effect extraction pre-specified(most serious outcome) Favors lanadelumab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ COMMUNITY Amgen (DB RCT) -7% 1.07 [0.48-2.35] 8/25 9/30 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.88 Late treatment -7% 1.07 [0.48-2.35] 8/25 9/30 7% higher risk All studies -7% 1.07 [0.48-2.35] 8/25 9/30 7% higher risk 1 lanadelumab COVID-19 RCT mortality result c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.88 Favors lanadelumab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ COMMUNITY Amgen (DB RCT) -7% 1.07 [0.48-2.35] death 8/25 9/30 Improvement, RR [CI] Treatment Control COMMUNITY Amgen (DB RCT) 10% 0.90 [0.45-1.78] no improv. 9/25 12/30 COMMUNITY Amgen (DB RCT) 24% 0.76 [0.35-1.67] no disch. 7/25 11/30 COMMUNITY Amgen (DB RCT) -9% 1.09 [0.56-2.14] no recov. 10/25 11/30 Lanadelumab COVID-19 outcomes c19early.org December 2025 Favors lanadelumab Favors control